On June 24, 2024, Biocon Ltd informed in a stock exchange filing that the company’s subsidiary, Biocon Biologics Ltd (BBL), has obtained approval from the European Medicines Agency (EMA) to commence manufacturing biosimilar Bevacizumab at its newly established monoclonal antibodies (mAbs) drug substance facility in Bengaluru. This approval marks a significant milestone, enhancing BBL’s capacity …